Craigavon-headquartered pharmaceutical organisation Almac Group has posted record financial results for the year ending 30 September, with revenues rising 7% to £1.1 billion, pre-tax profit climbing 16% to £138.9 million, and global employee numbers growing 6% to approximately 7,900, according to The Irish News.

The results mark the highest levels of revenue, profit, and staffing in the company's 24-year history since its founding in 2002 by the late Co Tyrone entrepreneur Sir Allen McClay.

Alan Armstrong, chairman and chief executive of Almac Group, said: "These results reflect another successful year for Almac and demonstrate the resilience of our long-term growth strategy in a changing global environment. As a privately owned company, we are proud to reinvest our profits to support our global clients, drive innovation and expand our capabilities."

The record results mark the fifth year of Almac's £500 million-plus global capital investment programme, first announced in November 2021. Since the programme's launch, employee numbers have increased by more than 2,000, with more than half of these new roles created in Northern Ireland.

The investment programme spans diagnostic and pharmaceutical development and manufacturing, clinical production and distribution, commercial manufacturing and packaging, global cold-chain infrastructure, and analytical services.

Almac, which operates from 18 facilities across Europe, the United States, and Asia, supported the development and ongoing commercial supply of hundreds of medicines across more than 20 therapeutic areas during the financial year, including oncology, cardiology, immunology, gene therapy, and neurology.

The company reinvests all profits back into the business to support long-term growth, a model that has underpinned its sustained expansion across global pharmaceutical development and manufacturing markets.

Read the full report for further detail on Almac Group's record financial results and investment programme.